An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 211962
Company: XELLIA PHARMS APS

Products on NDA 211962

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes
VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes
VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes
VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes
VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes
VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes
VANCOMYCIN HYDROCHLORIDE	VANCOMYCIN HYDROCHLORIDE	EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 211962

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
02/15/2019	ORIG-1	Approval	Type 5 - New Formulation or New Manufacturer	PRIORITY	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211962s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211962Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211962Orig1s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
01/29/2021	SUPPL-11	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211962s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211962Orig1s011ltr.pdf
05/28/2021	SUPPL-9	Efficacy-New Patient Population	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211962s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211962Orig1s009ltr.pdf
09/03/2020	SUPPL-3	Labeling-Proprietary Name Change	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211962s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211962Orig1s003ltr.pdf

Labels for NDA 211962

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
05/28/2021	SUPPL-9	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211962s009lbl.pdf
01/29/2021	SUPPL-11	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211962s011lbl.pdf
09/03/2020	SUPPL-3	Labeling-Proprietary Name Change	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211962s003lbl.pdf
02/15/2019	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211962s000lbl.pdf

Top